Ever Supreme Bio Technology Statistics
Total Valuation
Ever Supreme Bio Technology has a market cap or net worth of TWD 14.24 billion. The enterprise value is 13.60 billion.
Market Cap | 14.24B |
Enterprise Value | 13.60B |
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024.
Earnings Date | Nov 5, 2024 |
Ex-Dividend Date | May 29, 2024 |
Share Statistics
Ever Supreme Bio Technology has 80.67 million shares outstanding. The number of shares has decreased by -1.60% in one year.
Shares Outstanding | 80.67M |
Shares Change (YoY) | -1.60% |
Shares Change (QoQ) | -0.05% |
Owned by Insiders (%) | 2.32% |
Owned by Institutions (%) | 2.79% |
Float | 58.43M |
Valuation Ratios
The trailing PE ratio is 28.15.
PE Ratio | 28.15 |
Forward PE | n/a |
PS Ratio | 17.38 |
PB Ratio | 9.24 |
P/FCF Ratio | 34.07 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 31.45, with an EV/FCF ratio of 32.54.
EV / Earnings | 26.62 |
EV / Sales | 16.51 |
EV / EBITDA | 31.45 |
EV / EBIT | 33.80 |
EV / FCF | 32.54 |
Financial Position
The company has a current ratio of 3.65, with a Debt / Equity ratio of 0.55.
Current Ratio | 3.65 |
Quick Ratio | 3.17 |
Debt / Equity | 0.55 |
Debt / EBITDA | 0.02 |
Debt / FCF | 0.02 |
Interest Coverage | 2,578.63 |
Financial Efficiency
Return on equity (ROE) is 30.34% and return on invested capital (ROIC) is 14.85%.
Return on Equity (ROE) | 30.34% |
Return on Assets (ROA) | 13.19% |
Return on Capital (ROIC) | 14.85% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.43 |
Inventory Turnover | 2.64 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.69% in the last 52 weeks. The beta is 0.29, so Ever Supreme Bio Technology's price volatility has been lower than the market average.
Beta (5Y) | 0.29 |
52-Week Price Change | -0.69% |
50-Day Moving Average | 188.66 |
200-Day Moving Average | 186.39 |
Relative Strength Index (RSI) | 35.69 |
Average Volume (20 Days) | 245,092 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ever Supreme Bio Technology had revenue of TWD 823.57 million and earned 510.71 million in profits. Earnings per share was 6.27.
Revenue | 823.57M |
Gross Profit | 576.86M |
Operating Income | 402.27M |
Pretax Income | 602.60M |
Net Income | 510.71M |
EBITDA | 420.73M |
EBIT | 402.27M |
Earnings Per Share (EPS) | 6.27 |
Balance Sheet
The company has 649.78 million in cash and 8.53 million in debt, giving a net cash position of 641.24 million or 7.95 per share.
Cash & Cash Equivalents | 649.78M |
Total Debt | 8.53M |
Net Cash | 641.24M |
Net Cash Per Share | 7.95 |
Equity (Book Value) | 1.54B |
Book Value Per Share | 19.10 |
Working Capital | 624.95M |
Cash Flow
In the last 12 months, operating cash flow was 421.09 million and capital expenditures -3.20 million, giving a free cash flow of 417.89 million.
Operating Cash Flow | 421.09M |
Capital Expenditures | -3.20M |
Free Cash Flow | 417.89M |
FCF Per Share | 5.18 |
Margins
Gross margin is 70.04%, with operating and profit margins of 48.84% and 62.01%.
Gross Margin | 70.04% |
Operating Margin | 48.84% |
Pretax Margin | 73.17% |
Profit Margin | 62.01% |
EBITDA Margin | 51.09% |
EBIT Margin | 48.84% |
FCF Margin | 50.74% |
Dividends & Yields
This stock pays an annual dividend of 5.45, which amounts to a dividend yield of 3.07%.
Dividend Per Share | 5.45 |
Dividend Yield | 3.07% |
Dividend Growth (YoY) | 231.16% |
Years of Dividend Growth | n/a |
Payout Ratio | 86.16% |
Buyback Yield | 1.60% |
Shareholder Yield | 4.68% |
Earnings Yield | 3.55% |
FCF Yield | 2.93% |
Stock Splits
The last stock split was on May 29, 2024. It was a forward split with a ratio of 1.1000011.
Last Split Date | May 29, 2024 |
Split Type | Forward |
Split Ratio | 1.1000011 |